Module 3 2019

Formulation Considerations

➢ Excipient compatibility (chemical) o Change of polymorphic form on compression? ➢ Dosage form: oral, parenteral, topical? o Simple tablet or sustained release? o Injection, infusion or concentrate? ➢ Stability ➢ Who will manufacture commercial batches? o In-house or contractor? o What do they need to know? o Location?

18